Table 2.
Summary of the types and characteristics of candidate galectin inhibitors that have entered or may enter clinical evaluation in the context of cancer therapy.
| Galectin Inhibitor | Target Galectin | Drug type | Recipient medical condition | Clinical Trial ID |
|---|---|---|---|---|
| PectaSol-C MCP (Modified Citrus Pectin) | Gal-3 | Modified large complex carbohydrate | Biochemically relapsed prostate cancer (BRPC) | NCT01681823 |
| GCS-100 (Modified Citrus Pectin) | Gal-3 | Modified large complex carbohydrate | Chronic Lymphocytic Leukemia | NCT00514696 |
| GR-MD-02 (Belapectin) | Gal-3 | Modified large complex carbohydrate | Melanoma, Non-small Cell Lung Cancer, Squamous Cell Head and Neck Cancer, | NCT02575404, NCT02117362 |
| GB1211 | Gal-3 | Small molecule | Healthy subjects for evaluation of safety and tolerability, NSCLC | NCT03809052, NCT05240131 |
| GM-CT-01 (DAVANAT) | Gal-3 (and potentially Gal-1 (154),) | Modified large complex carbohydrate | Colorectal Cancer, Prostate Cancer, Lung Cancer, Head and Neck Cancer, Breast Cancer | NCT00054977 |
| OTX008 | Gal-1 | Small molecule | Solid Tumors | NCT01724320 |
| AP-74 M-545 | Gal-1 | DNA aptamer | Lung cancer | Currently not under clinical investigation |
| Lyt200 | Gal-9 | Monoclonal antibody | Metastatic Solid Tumors (Cholangiocarcinoma, Pancreatic Cancer, Colorectal Cancer) | NCT04666688 |